相关实验视频
Updated: Jun 27, 2026

10:32
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 28, 2014
功能边界相关的巨细胞限制了阿尔茨海默病的进展
bioRxiv : the preprint server for biology
|February 12, 2026
概括
边界相关的巨细胞 (BAMs) 在阿尔茨海默病 (AD) 和脑粉样血管病变 (CAA) 中至关重要. 维护BAM功能为这些神经退行性疾病提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 大脑寄存的巨细胞,包括微质细胞和与边界相关的巨细胞 (BAMs),都与阿尔茨海默病 (AD) 的发病有关.
- 在阿尔茨海默病中解开微质与BAMs的特定作用一直是个挑战.
- 通过AD GWAS研究确定的Maf基因对BAM存活至关重要,但不是微质存活.
研究的目的:
- 调查BAMs对阿尔茨海默病 (AD) 和大脑粉样血管病变 (CAA) 进展的贡献.
- 探索在AD病变过程中BAMs的功能变化.
- 评估在AD中维护BAM功能的治疗潜力.
主要方法:
- 使用BAM枯竭的小鼠与5xFAD AD模型交叉.
- 分析了大脑粉样蛋白血管病变 (CAA),β-粉样蛋白负担和神经退行症的标志物.
- 在AD模型和人类样本中评估了BAM和微质内细胞容量和代谢状态.
主要成果:
- 在AD模型中BAM耗尽加剧了脑粉样血管病变 (CAA),增加了β-粉样荷载,加速了神经退行和记忆缺陷.
- 在健康的大脑中,BAMs比微质细胞更高地吸收β-粉样蛋白.
- 在阿尔茨海默病进展过程中,BAMs的数量减少,内细胞功能受损,代谢疲劳比微质细胞更早.
结论:
- BAM在缓解AD和CAA病理方面发挥着关键的保护作用.
- BAM功能障碍,其特点是数量减少和细胞能力受损,对AD的进展有显著的贡献.
- 旨在保护或恢复BAM功能的策略代表了阿尔茨海默病和脑粉样血管病变的有前途的新疗法.
更多相关视频
相关概念视频
Microtubule Associated Proteins (MAPs)
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
Microtubule Instability
Microtubules are hollow cylindrical filaments having a diameter of approximately 25 nm and a length that varies from 200 nm to 25 μm. GTP-bound tubulin subunits form αβ-heterodimers for microtubule assembly. These core building blocks interact longitudinally, polymerizing into protofilaments. The protofilaments then interact with one another through lateral bonding forces to form stable cylindrical microtubules. These cylindrical filaments are dynamic as they undergo repeated assembly and...
Regulation of Metabolism
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

